The Belgian biotech has regained the rights to an early-stage IDO1 inhibitor that has failed a Phase I trial but iTeos believes the drug's penetration to the brain makes EOS200271 a significant asset.
News that Pfizer Inc. is returning the rights to its indoleamine 2,3-dioxygenase (IDO1) inhibitor is a surprise but represents an opportunity for iTeos Therapeutics SA, according to the Belgian biotech's CEO Michel Detheux.
It has been confirmed this morning (Jan. 4) that the US behemoth has handed back worldwide rights to EOS200271, an...
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.
Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
